Synthesis method of heterocyclic compound

Through mild conditions such as Grignard reaction and halogenation reaction, the problems of low-temperature sensitive and highly toxic reagents in the synthesis of baroxavir intermediates are solved, and safe, environmentally friendly and low-cost synthesis is achieved, which is suitable for industrial production.

CN119080593APending Publication Date: 2024-12-06SUNSHINE LAKE PHARMA CO LTD
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202411120300.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2020-03-07
Filing Date
2021-03-05
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

The existing synthesis methods of baroxavir intermediates have problems such as low temperature sensitive reactions, strict operating and storage conditions, high raw material prices, the use of highly toxic reagents and post-treatment to produce a large amount of waste acid, which makes it unsuitable for commercial production.

Method used

Using mild conditions such as Grignard reaction and halogenation reaction, non-toxic reagents and solvents were used to obtain baroxavir intermediates through multiple steps, avoiding the use of toxic substances such as phenylthiophene and simplifying the post-treatment. process.

Benefits of technology

It realizes safe, environmentally friendly and low-cost synthesis of baroxavir intermediates, reduces production costs, improves product yield and purity, and is suitable for industrial production.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_2
    Figure SMS_2
  • Figure SMS_3
    Figure SMS_3
Patent Text Reader

Abstract

The invention relates to a synthetic method of a heterocyclic compound, and belongs to the field of medicinal chemistry. The synthetic method of the heterocyclic compound comprises the following steps: carrying out Grignard reaction on raw materials, carrying out condensation, reacting the obtained product with a halogenating agent in the presence of an initiator, and carrying out reaction and post-treatment in the presence of alkali to obtain the heterocyclic compound. The scheme provided by the invention has the advantages of safety, environmental protection, low cost, high purity, high yield and the like, and is beneficial to industrial production.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of medicinal chemistry, and more specifically to a method for synthesizing heterocyclic compounds. Background Technology

[0002] Baloxavir (marboxil) is an innovative Cap-dependent endonuclease inhibitor used to treat influenza A and B. Baloxavir's advantages include fewer doses and a longer duration of action; its chemical structure is as follows:

[0003]

[0004] Currently, there are few publicly disclosed methods for synthesizing baloxavir and its intermediates. In the prior art, the intermediates for synthesizing baloxavir involve a heterocyclic compound. Among them, patent CN109311911A discloses a method for preparing the fragment intermediate 8-difluorodibenzo[b,e]thiaheptacyclo-11(6H)-ol (i.e., compound 6 in the following route).

[0005]

[0006] This patent involves two low-temperature sensitive reactions (the first reaction requires cooling to -40°C), using LDA (lithium diisopropylaminophosphate) or directly preparing LDA (lithium diisopropylaminophosphate), requiring stringent operational and material storage conditions. Furthermore, the reagents and solvents required for the reaction must be strictly dehydrated, making the conditions extremely demanding. The second reaction uses thiophenol, a reagent with a pungent odor and extremely high toxicity upon inhalation. It is listed as a highly toxic chemical and its purchase and use are restricted. It poses a significant hazard to production personnel and the environment, placing even higher demands on production plant construction, making it unsuitable for commercial production.

[0007] Patents CN 110105327 A and CN 109134428 A disclose a method for synthesizing 6 using compound 7 as a material, as shown in the following route:

[0008]

[0009] This route uses 2-bromomethyl-3,4-difluorophenylacetonitrile as a raw material. On one hand, the preparation of cyano groups involves highly toxic controlled substances such as potassium cyanide and sodium cyanide; on the other hand, the route for preparing cyano groups using amides is lengthy and the raw materials are very expensive. Industrial production faces challenges due to the difficulty in obtaining and high cost of raw materials caused by regulations. Although sodium thiophene is used instead of thiophene, this route still inevitably produces thiophene. Furthermore, sodium thiophene is also a controlled chemical.

[0010] The literature *Organic Process Research & Development*, 23(12), 2716-2723; 2019, reports an alternative synthetic route:

[0011]

[0012] This route uses 2-bromomethyl-3,4-difluorophenylacetonitrile (i.e., compound 8) as a raw material. While the second step of the reaction uses diphenyl sulfide, which reduces the odor compared to thiophenol or sodium thiophenol used in the previously described routes, the pungent odor of thiophenol still occurs during operation, requiring careful handling to minimize toxicity. The fourth step uses a large equivalent of PPA (polyphthalamide), resulting in a large amount of waste acid generated during post-treatment, causing significant pollution and hindering industrial-scale production.

[0013] In summary, the existing techniques for synthesizing heterocyclic compounds of baloxavir intermediates and their analogues have at least one of the following drawbacks:

[0014] (1) It involves low-temperature sensitive reactions, and the operation and material storage conditions are highly demanding;

[0015] (2) Strict moisture removal is required, and the conditions are harsh;

[0016] (3) The reaction involves highly toxic and foul-smelling reagents, the purchase and use of which are regulated and pose a great hazard to production personnel and the environment;

[0017] (4) The raw materials for pharmaceuticals are expensive;

[0018] (5) Post-treatment easily generates a large amount of waste acid, which causes great pollution and is not conducive to industrial production.

[0019] Therefore, we still need a safe, environmentally friendly, low-cost, and simple method for synthesizing baloxavir intermediates or their analogues. Summary of the Invention

[0020] To address the above problems, this invention provides a method for preparing baloxavir intermediates.

[0021] In a first aspect, the present invention provides a method for preparing a compound of formula (B), comprising:

[0022]

[0023] Compound (A) undergoes a Grignard reaction with a Grignard reagent in the first reaction solvent under the protection of an inert gas, and then reacts with compound (F). After a first post-treatment, compound (B) is obtained, wherein R1 is selected from chlorine, bromine and iodine; and R5 is selected from methyl, ethyl, isopropyl, tert-butyl and carbonyl chloride.

[0024] The Grignard reagent includes at least one selected from isopropyl magnesium chloride, isopropyl magnesium bromide, methyl magnesium bromide, methyl magnesium chloride, and isopropyl magnesium chloride-lithium chloride. In some embodiments, the Grignard reagent is isopropyl magnesium chloride or isopropyl magnesium bromide.

[0025] The first reaction solvent includes at least one selected from tetrahydrofuran and methyltetrahydrofuran.

[0026] The Grignard reaction is carried out at a temperature of -10°C to 10°C. In some embodiments, the Grignard reaction is carried out at a temperature of -5°C to 5°C. In some embodiments, the Grignard reaction is carried out at a temperature of 0°C.

[0027] The reaction temperature with the compound of formula (F) is -10°C to 10°C. In some embodiments, the reaction temperature with the compound of formula (F) is -5°C to 5°C. In some embodiments, the reaction temperature with the compound of formula (F) is 0°C.

[0028] The molar ratio of compound (A) to Grignard reagent can be 1:0.9-1:1.3. In some embodiments, the molar ratio of compound (A) to Grignard reagent is 1:1-1.2. In some embodiments, the molar ratio of compound (A) to compound (F) is 1:0.9-1:1.3. In some embodiments, the molar ratio of compound (A) to compound (F) is 1:1-1.2.

[0029] The inert gas can be any suitable gas that does not participate in the reaction, such as nitrogen.

[0030] The first post-processing includes: quenching with water, separation, extraction with a first organic solvent, combining the organic layers, and vacuum distillation of the combined organic layers. The organic solvent is selected from ethyl acetate.

[0031] In a second aspect, the present invention provides a method for preparing a compound of formula (C), comprising:

[0032]

[0033] Compound (B) undergoes a halogenation reaction with a halogenating agent in the second reaction solvent in the presence of an initiator, followed by a second post-treatment to obtain compound (C), wherein R2 is selected from chlorine, bromine, or iodine.

[0034] The second reaction solvent includes at least one selected from dichloromethane, chloroform, carbon tetrachloride, petroleum ether, n-hexane, n-heptane, n-hexane, cyclohexane, heptane, 1,2-dichloroethane, and ethyl acetate. In some embodiments, the second reaction solvent is dichloromethane, which is beneficial for the reaction to proceed and for obtaining the target product.

[0035] The initiator includes at least one selected from benzoyl peroxide, lauroyl peroxide, cumene hydroperoxide, tert-butyl hydroperoxide, tert-butyl peroxide, tert-butyl pervalerate, methyl ethyl ketone peroxide, cyclohexanone peroxide, diisopropyl percarbonate, dicyclohexyl percarbonate, azobisisobutyronitrile, and azobisisoheptanenitrile. In some embodiments, the initiator is azobisisobutyronitrile or azobisisoheptanenitrile, or a combination thereof, which is beneficial for reaction control and execution.

[0036] The halogenating agent includes at least one selected from N-bromosuccinimide, dibromohydantoin, bromine, N-chlorosuccinimide, and N-iodosuccinimide. In some embodiments, the halogenating agent is N-bromosuccinimide, N-chlorosuccinimide, N-iodosuccinimide, or a combination thereof.

[0037] The halogenation reaction is carried out at a temperature of 30°C-80°C. In some embodiments, the halogenation reaction is carried out at a temperature of 35°C-70°C. In some embodiments, the halogenation reaction is carried out at a temperature of 40°C-60°C. In some embodiments, the halogenation reaction is carried out at a temperature of 45°C-55°C.

[0038] The molar ratio of the compound of formula (B) to the initiator is 1:0.1 to 1:0.5. In some embodiments, the molar ratio of the compound of formula (B) to the initiator is 1:0.2 to 1:0.4.

[0039] The second post-treatment includes: quenching with an aqueous sodium sulfite solution, separation, washing the organic phase with water, and concentrating the organic phase under reduced pressure.

[0040] The sodium sulfite aqueous solution has a mass percentage concentration of 5%-25%.

[0041] Thirdly, the present invention provides a method for preparing a compound of formula (D), comprising:

[0042]

[0043] Compound (C) is reacted with compound (K) in a third reaction solvent in the presence of a first base, followed by a third post-treatment to obtain compound (D), wherein R2 is selected from chlorine, bromine, and iodine; M is selected from sulfur and oxygen; R3 is selected from H, aryl, and C1-C6 alkyl; and R4 is selected from hydrogen, potassium, and sodium.

[0044] The third reaction solvent includes at least one selected from acetone, tetrahydrofuran, toluene, and water. In some embodiments, the third reaction solvent is acetone, tetrahydrofuran, water, or a combination thereof, which is more conducive to the reaction.

[0045] The first base comprises at least one selected from triethylamine, sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, sodium bicarbonate, potassium bicarbonate, 1,8-diazabicycloundec-7-ene, and N,N-diisopropylethylamine. In some embodiments, the first base is triethylamine, 1,8-diazabicycloundec-7-ene, N,N-diisopropylethylamine, or a combination thereof.

[0046] The reaction temperature with the compound of formula (K) is 5°C-40°C. In some embodiments, the reaction temperature with the compound of formula (K) is 10°C-30°C. In some embodiments, the reaction temperature with the compound of formula (K) is 20°C.

[0047] The molar ratio of the first alkali to the compound of formula (C) is not less than 1:1.

[0048] The molar ratio of compound (K) to compound (C) is 0.9:1 to 1.5:1.

[0049] The third post-processing includes: vacuum concentration, addition of a third organic solvent with stirring, extraction, combining the organic phases, and vacuum concentration of the combined organic phases. The third organic solvent may include or be dichloromethane.

[0050] Fourthly, the present invention provides a method for preparing a compound of formula (E), comprising:

[0051]

[0052] Compound (D) is reacted with a second base in a fourth reaction solvent, followed by a fourth post-treatment to obtain compound (E), wherein M is selected from sulfur and oxygen; and R3 is selected from H, C1-C6 alkyl, and aryl.

[0053] The fourth reaction solvent includes at least one selected from methanol, ethanol, isopropanol, dichloromethane, ethyl acetate, isopropyl acetate, toluene, acetone, n-heptane, and cyclohexane. In some embodiments, the fourth reaction solvent is methanol or ethanol, or a combination thereof.

[0054] The second base includes at least one selected from sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, sodium bicarbonate, potassium bicarbonate, triethylamine, diisopropylethylamine, pyridine, 1,8-diazabicycloundec-7-ene, and N,N-diisopropylethylamine. In some embodiments, the second base is potassium carbonate, which is beneficial for obtaining the target product.

[0055] The reaction temperature with the second alkali is 10°C-60°C. In some embodiments, the reaction temperature with the second alkali is 20°C-50°C. In some embodiments, the reaction temperature with the second alkali is 30°C-40°C.

[0056] The molar ratio of the second base to the compound of formula (D) is not less than 0.9:1.

[0057] The fourth post-processing includes: vacuum concentration, addition of a fourth organic solvent and water, extraction, merging of organic phases, concentration of the merged organic phases, and recrystallization.

[0058] The fourth organic solvent includes or may be dichloromethane.

[0059] The recrystallization includes recrystallization with acetone.

[0060] In some embodiments, a method for preparing a compound includes at least one of the methods described above.

[0061] In some embodiments, a method for preparing a compound of formula (E) includes: preparing a compound of formula (D) using the aforementioned method, then reacting the compound of formula (D) with a second base in a fourth reaction solvent, followed by a fourth post-treatment to obtain a compound of formula (E).

[0062] In some embodiments, a method for preparing compound (E) includes: reacting compound (A) with a Grignard reagent in a first reaction solvent under the protection of an inert gas, followed by a reaction with compound (F), and undergoing a first post-treatment to obtain compound (B); reacting compound (B) with a halogenating agent in a second reaction solvent in the presence of an initiator, and undergoing a second post-treatment to obtain compound (C); reacting compound (C) with compound (K) in a third reaction solvent in the presence of a first base, and undergoing a third post-treatment to obtain compound (D); then reacting compound (D) with a second base in a fourth reaction solvent, and undergoing a fourth post-treatment to obtain compound (E); each compound is as described above.

[0063] Fifthly, the present invention provides a compound having the structure shown in compound (B):

[0064]

[0065] In a sixth aspect, the present invention provides a compound having the structure shown in compound (C):

[0066]

[0067] R2 is selected from chlorine, bromine, and iodine.

[0068] In a seventh aspect, the present invention provides a compound having the structure shown in compound (D):

[0069]

[0070] M is selected from sulfur and oxygen; R3 is selected from H, aryl and C1-C6 alkyl.

[0071] Beneficial effects:

[0072] Compared with the prior art, the technical solution of the present invention has at least one of the following technical effects:

[0073] (1) The reaction conditions are mild, which is conducive to industrial production;

[0074] (2) The raw materials for pharmaceuticals are inexpensive and readily available;

[0075] (3) It is safe and environmentally friendly, and is not likely to cause harm to production personnel and the environment. It avoids the use of highly toxic substances such as thiophenol or diphenyl sulfide used in the usual literature process (thiophenol and diphenyl sulfide are controlled products and have a strong odor, which is not good for the environment and health).

[0076] (4) The post-treatment process is simple and environmentally friendly;

[0077] (5) Low production cost, which is conducive to industrialized production;

[0078] (6) The product has a high yield and high purity.

[0079] Terminology Explanation:

[0080] g represents grams, mg represents milligrams, ℃ represents degrees Celsius, h represents hours, mL represents milliliters, min represents minutes, mol represents moles, and mmol represents millimoles.

[0081] In the description of this invention, it should be understood that the terms "first" and "second" are used for descriptive purposes only and should not be construed as indicating or implying relative importance or implicitly specifying the number of indicated technical features. Therefore, a feature defined as "first" or "second" may explicitly or implicitly include one or more of that feature. In the description of this invention, "a plurality of" means two or more, unless otherwise explicitly specified.

[0082] In the description of this specification, the references to terms such as "one embodiment," "some embodiments," "example," "specific example," or "some examples," etc., indicate that a specific feature, structure, material, or characteristic described in connection with that embodiment or example is included in at least one embodiment or example of the present invention. In this specification, the illustrative expressions of the above terms do not necessarily refer to the same embodiment or example. Furthermore, the specific features, structures, materials, or characteristics described may be combined in any suitable manner in one or more embodiments or examples. Moreover, without contradiction, those skilled in the art can combine and integrate the different embodiments or examples described in this specification, as well as the features of different embodiments or examples.

[0083] In this invention, expressions such as "compound A" and "compound represented by formula A" refer to the same compound. Detailed Implementation

[0084] To enable those skilled in the art to better understand the technical solutions of the present invention, some non-limiting embodiments are further disclosed below to provide a more detailed description of the present invention.

[0085] All reagents used in this invention can be purchased commercially or prepared by the methods described in this invention.

[0086] Example 1 Preparation of compound (B)

[0087]

[0088] 10.00 g of compound (L) and 10.00 g of tetrahydrofuran were mixed, cooled to 0 °C, and under nitrogen protection, 72.46 ml of 1 mol / ml isopropyl magnesium chloride tetrahydrofuran solution was slowly added dropwise. After the addition was complete, the mixture was reacted at 0 °C for 24 hours. The remaining compound (L) was detected by high performance liquid chromatography, and solution 1 was obtained. 8.19 g of methyl o-fluorobenzoate was dissolved in 50.00 g of tetrahydrofuran to obtain a methyl o-fluorobenzoate tetrahydrofuran solution. The solution was cooled to 0 °C, and then added to the methyl o-fluorobenzoate tetrahydrofuran solution. The reaction was continued at 0 °C for 4 h. The main product compound (B) was detected by high performance liquid chromatography. 30 mL of water was added to quench the reaction. After the addition was complete, the mixture was stirred at 10 °C-30 °C, separated, and the aqueous layer was extracted once with 10 mL of ethyl acetate. The organic layers were combined and washed once with 10 mL of water. The organic layer was then distilled under reduced pressure at 40 °C to obtain 10.87 g of compound (B) (yield 90%, purity 95.0%). The obtained compound (B) was analyzed by mass spectrometry and proton NMR. The results are as follows:

[0089] GC-MS: [M] = 249.0;

[0090] 1H-NMR (400MHz, d-DMSO) δ7.69-7.71(m,1H),7.61-7.65(m,1H),7.32-7.40(m,3H),7.24-7.26(m,1H),2.31-2.32(d,3H).

[0091] Example 2 Preparation of compound (H)

[0092]

[0093] Take 3.00 g of compound (B), 30 mL of dichloromethane, 2.34 g of N-bromosuccinimide and 0.06 g of azobisisobutyronitrile, mix them, stir and heat to 50 °C, reflux until no compound (B) remains as detected by high performance liquid chromatography, add 30 mL of 5% sodium sulfite aqueous solution to quench, separate the liquid and wash the organic phase with water (10 mL × 2 times), distill under reduced pressure at 40 °C to obtain 3.90 g of compound (H) (semi-solid, yield 99.0%, purity 95.2%); detect the mass spectrometry of compound (H), the result is as follows: MS: [M+1] = 330.1.

[0094] Example 3 Preparation of compound (I)

[0095]

[0096] 3.50 g of compound (H) was dissolved in 17.5 mL of acetone and 17.5 mL of water. 1.46 g of potassium thioacetate and 1.61 g of triethylamine were added with stirring. The reaction was carried out at 20 °C until no compound (H) remained as detected by high performance liquid chromatography. The mixture was concentrated under reduced pressure at 40 °C, and 20 mL of dichloromethane was added and stirred for 10 min. The mixture was extracted, separated, and the organic phase was washed twice with 10 mL of water. The mixture was then concentrated under reduced pressure at 40 °C to obtain 3.65 g of compound (I) (yellow solid, yield 95.0%, purity 94.8%). The obtained compound (I) was analyzed by mass spectrometry and proton NMR. The results are as follows:

[0097] MS:[M+1]=325.20;

[0098] 1H NMR (400MHz, CDCl3): δ7.94(m,1H),7.76(m,1H),7.41(m,1H),7.34(m,1H),7.32(m,1H),7.13(m,1H),4.59(s,2H),2.30(s,3H).

[0099] Example 4 Preparation of compound (J)

[0100]

[0101] Weigh 3.24 g of compound (I), add 15 ml of methanol and 4.0 g of potassium carbonate, stir at 10℃-60℃ for 3 h, and detect by high performance liquid chromatography. Once no compound (I) remains, concentrate under reduced pressure to remove the solvent, add 15 ml of dichloromethane and 5 ml of water, extract, separate, concentrate the organic phase, and recrystallize with 6 ml of acetone to obtain 2.3 g of compound (J) (yield 88%, purity 95%). Analyze the obtained compound (J) using 1H NMR and mass spectrometry. The results are as follows:

[0102] 1H NMR (400MHz, CDCl3): δ8.19(dd,1H),7.38(m,3H),7.28(m,1H),7.12(m,1H),4.13(s,2H);

[0103] MS:[M+1]=263.02.

[0104] The method of this invention has been described through preferred embodiments. Those skilled in the art will readily be able to modify or appropriately alter and combine the methods and applications described herein within the scope, spirit, and context of this invention to implement and apply the technology of this invention. Those skilled in the art can refer to the content herein to appropriately improve process parameters. It should be particularly noted that all similar substitutions and modifications are obvious to those skilled in the art and are considered to be included within the scope of this invention.

Claims

1. A method for preparing a compound of formula (C), comprising: The compound of formula (B) undergoes a halogenation reaction with a halogenating agent in the presence of an initiator in a second reaction solvent, and undergoes a second post-treatment to obtain a compound of formula (C), wherein R2 is selected from chlorine, bromine or iodine.

2. The method for preparing a compound of formula (C) according to claim 1, characterized in that: The second reaction solvent comprises at least one selected from the group consisting of dichloromethane, chloroform, carbon tetrachloride, petroleum ether, n-hexane, n-heptane, n-hexane, cyclohexane, heptane, 1,2-dichloroethane and ethyl acetate; and / or The initiator comprises at least one selected from benzoyl peroxide, lauroyl peroxide, cumene hydroperoxide, tert-butyl hydroperoxide, tert-butyl perbenzoate, tert-butyl pervalerate, methyl ethyl ketone peroxide, cyclohexanone peroxide, diisopropyl peroxydicarbonate, dicyclohexyl peroxydicarbonate, azobisisobutyronitrile and azobisisoheptylonitrile; and / or The halogenating agent is selected from at least one of N-bromosuccinimide, dibromohydantoin, bromine, N-chlorosuccinimide and N-iodosuccinimide.

3. The method for preparing a compound of formula (C) according to claim 1 or 2, characterized in that: The temperature of the halogenation reaction is 30°C-80°C; and / or The molar ratio of the compound of formula (B) to the initiator is 1:0.1-1:0.5; and / or The molar ratio of the compound of formula (B) to the halogenating agent is 1:0.9-1:1.

5.

4. The method for preparing a compound of formula (C) according to claim 1, wherein the method for preparing a compound of formula (C) further comprises a method for preparing a compound of formula (B), wherein the method for preparing a compound of formula (B) comprises: The compound of formula (A) undergoes a Grignard reaction with a Grignard reagent in a first reaction solvent under the protection of an inert gas, and then reacts with a compound of formula (F), and undergoes a first post-treatment to obtain a compound of formula (B), wherein R1 is selected from chlorine, bromine and iodine; and R5 is selected from methyl, ethyl, isopropyl, tert-butyl and carbonyl chloride.

5. The method for preparing a compound of formula (C) according to claim 4, wherein the Grignard reagent comprises at least one selected from isopropylmagnesium chloride, isopropylmagnesium bromide, methylmagnesium bromide, methylmagnesium chloride and isopropylmagnesium chloride-lithium chloride; and / or The temperature of the Grignard reaction is -10°C to 10°C; and / or The molar ratio of the compound of formula (A) to the Grignard reagent is 1:0.9-1:1.

3.

6. The method for preparing the compound of formula (C) according to claim 4 or 5, wherein the temperature of the reaction with the compound of formula (F) is -10°C to 10°C; The molar ratio of the compound of formula (A) to the compound of formula (F) is 1:0.9-1:1.3; and / or The first post-processing comprises: Add water to quench, stir at 10°C-30°C, extract, combine the organic layers, and evaporate under reduced pressure.

7. A compound whose structure is selected from the compound of formula (B):

Citation Information

Patent Citations

  • Preparation method of baloxavir marboxil intermediate

    CN109134428A

  • Method for producing substituted polycyclic pyridone derivative and crystal of same

    CN109311911A

  • Preparation method of 7,8-difluoro-6,11-dihydro-dibenzothiophene-11-alcohol

    CN110105327A